Core Viewpoint - Weigao Blood Purification, as the first leading enterprise in the blood purification sector to be listed on the A-share market, is seen as a bellwether for industry development, focusing on "long-termism" and innovation-driven growth since its listing on May 19 [1] Group 1: Company Strategy - The company emphasizes the importance of product development and technological innovation, committing to continuous R&D investment to maintain its technological edge [2] - Weigao Blood Purification is advancing its fundraising projects, planning to invest in intelligent production for blood purification and the development of new consumables and equipment [2] Group 2: R&D Investment - R&D has been a key focus for Weigao Blood Purification, with significant efforts in core products like blood dialysis machines and peritoneal dialysis solutions [3] - The company has consistently invested over 100 million annually in R&D, with planned investments of 183 million, 155 million, and 165 million yuan from 2022 to 2024, respectively [3] Group 3: Industry Positioning - Weigao Blood Purification has established a comprehensive industry chain covering key areas of blood purification, with products available in over 6,000 medical institutions nationwide [4] - The company’s innovative products, such as the first domestic neutral peritoneal dialysis solution, enhance patient quality of life and set benchmarks for product innovation in the industry [4] - Collaborations with companies like Nikkiso to introduce advanced technologies and localize improvements are driving technological upgrades in domestic blood purification equipment [4] Group 4: Future Outlook - The company is expected to continue leveraging innovation to create industrial value and lead industry development, with ongoing R&D outputs and the implementation of fundraising projects [4]

Core Insights - In May 2025, a total of 18 Chinese companies successfully completed IPOs across A-shares, Hong Kong, and US markets, raising a total of 50 billion yuan, with the energy and mining sector leading in fundraising [5][9][21]. Market Analysis - A-shares saw a significant decline in IPO activity, while the Hong Kong A+H listing track continued to gain momentum. The outlook for Chinese companies listing in the US remains uncertain [6][10][25]. - The number of IPOs in May 2025 increased by 38.46% year-on-year but decreased by 25% month-on-month. The total fundraising amount rose by 733% year-on-year and 142.42% month-on-month [9][21]. - The top five fundraising companies for the month included CATL, Hengrui Medicine, Junda Co., Weigao Medical, and Mirxes, with the energy and mining sector being the most concentrated industry for IPOs [7][21]. Performance Metrics - The first-day drop rate for IPOs was 22.22%, with four companies experiencing a decline on their debut [12][13]. - The highest first-day gain was recorded by Tiangong Co. at 411.93%, while the largest drop was by Pigeon Bio at -25.90% [13][14]. Sector and Regional Insights - The energy and mining sector led in fundraising with 346.16 billion yuan, accounting for 69.23% of the total IPO fundraising. The healthcare and advanced manufacturing sectors followed with 114.49 billion yuan and 14.16 billion yuan, respectively [44][50]. - Jiangsu province had the highest number of IPOs at four, while Fujian province led in total fundraising with 332.62 billion yuan [56][57]. Investment and Exit Analysis - In May 2025, 11 companies with VC/PE backing went public, with a total exit return of 12.4 billion yuan, reflecting a year-on-year increase of 67.57% [35][36]. - The average return on investment for VC/PE-backed IPOs was 2.16 times, showing a decline compared to previous periods [35][36]. Policy Developments - The Hong Kong Securities and Futures Commission announced a "Tech Company Fast Track" to facilitate the listing of tech and biotech companies [22][76]. - A series of financial policies were introduced by the People's Bank of China and other regulatory bodies to stabilize the market, including liquidity injections and increased loan quotas [17][78].

华泰联合证券有限责任公司关于 山东威高血液净化制品股份有限公司 三、培训成果 通过此次培训，威高血净董事、监事、高级管理人员等相关人员加深了对中 国证券监督管理委员会和上海证券交易所关于上市公司规范运作的了解和认识， 了解了违法违规行为的危害性，促使上述对象增强法制观念和诚信意识，加强理 解作为上市公司管理人员在公司规范运作方面所应承担的责任和义务。此次培训 有助于上市公司深刻认识到规范运作的重要性和违法违规的危害性，进而促使上 市公司进一步完善治理机制、规范内控制度，进一步提升威高血净的规范运作水 平。 (本页无正文,为《华泰联合证券有限责任公司关于山东威高血液净化制品股份 有限公司 2025 年度持续督导培训情况报告》之签章页) 2025 年度持续督导培训情况报告 上海证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》等有关规定以及威高血净的实际情况，对威高血净的董事、 监事、高级管理人员等相关人员进行了 202 ...

Core Points - C Youyou (301590) experienced a significant increase of 68.64% on its first trading day, with a turnover rate of 79.54% and a transaction volume of 1.022 billion yuan [1] - The stock's first-day margin trading saw a buy amount of 54.9874 million yuan, accounting for 5.38% of the total trading volume, with a latest margin balance of 48.6913 million yuan, representing 3.95% of the circulating market value [1] - The company specializes in the research, production, and sales of core components for direct current charging equipment for electric vehicles, with its main products being charging modules of various power levels [1] Fund Flow - On its debut, C Youyou attracted a net inflow of 343 million yuan from major funds, with large orders contributing 167 million yuan and 176 million yuan respectively [1] - The top five trading departments on the stock's first day had a combined transaction volume of 116 million yuan, with a net purchase of 67.0808 million yuan after accounting for sales [1] - One institutional special seat was listed, with a total net sell of 7.7741 million yuan [1]

Group 1: IPO Financing - In May 2025, 8 new stocks were issued in the A-share market, raising a total of 9.8 billion yuan, a month-on-month increase of 51.3%[10] - The average inquiry financing rate for new stocks was 118%, with 3 out of 7 new stocks exceeding their fundraising targets, representing 43% of the total[15] - The average fundraising amount per inquiry new stock was 1.4 billion yuan, up 33% month-on-month[15] Group 2: Valuation and Pricing - The average price-to-earnings (PE) ratio for new stocks in May was 19 times, a month-on-month increase of 26%[22] - The average discount of new stock PE relative to comparable companies was 41%, narrowing by 1.3 percentage points month-on-month[22] - The average admission rate for new stocks was 90%, down 5.5 percentage points from the previous month[29] Group 3: Initial Performance - The average first-day closing price increase for new stocks was 128%, a decrease of 88 percentage points month-on-month, maintaining a "zero break" status for the year[43] - The average return for 2 billion yuan preferential allocation products was 1.08%[52] - The first-day closing price premium for new stocks on the Beijing Stock Exchange was 412%, with a return rate of 0.47% for a 10 million yuan investment[54] Group 4: Regulatory Updates - Huadian New Energy's IPO registration became effective on May 16, 2025, with a planned fundraising of 18 billion yuan[67] - As of the end of May 2025, there were 101 IPO projects pending in the Shanghai and Shenzhen markets, with a total planned fundraising of 184.1 billion yuan[67] - The average review cycle for IPOs was 864 days, extending by 6% month-on-month[64]

Summary of Key Points Core Viewpoint - This week, one new stock will be available for subscription, following a significant increase in the stock market last week, where a new stock surged by 165% on its debut [2][3]. New Stock Subscription - One new stock, "新恒汇" (Xinhenghui), will be available for subscription on June 3, with a total issuance of approximately 5,988.89 million shares and an online issuance of about 1,437.3 million shares [3]. - The stock has a subscription limit of 1.40 million shares, and the top subscription requires a market value of 14 million yuan [3]. Recent Market Performance - Last week, the A-share market welcomed a new member, "古麒绒材" (Guqi Ruan Cai), which debuted on May 29, 2025, at an issuance price of 12.08 yuan and closed at 27.02 yuan, marking a first-day increase of 164.9% [4]. - The company specializes in high-specification down materials, primarily producing goose and duck down for use in clothing and bedding [4]. IPO and Financial Performance - This week, one company, 华新精科 (Huaxin Jingke), is undergoing IPO review, having submitted its application on March 3, 2023, and is sponsored by Huatai United Securities [5]. - In 2024, 华新精科 reported revenue of 1.421 billion yuan and a net profit of 153 million yuan [5]. - The company has significant revenue contributions from its projects with BMW, with income from this partnership accounting for 0.93%, 26.83%, and 25.33% of total revenue in different reporting periods [6]. IPO Guidance and Trends - There has been a 200% increase in IPO guidance filings, with three new companies added to the list [7][8].

Group 1 - The A-share IPO market has seen an increase in both the number of IPOs and the total fundraising amount in the first five months of the year, with 43 new IPOs raising a total of 28.202 billion yuan, a 3.74% increase year-on-year [1][2] - The majority of IPOs are concentrated in emerging industries, with significant contributions from the automotive, power equipment, and electronics sectors, which raised 7.221 billion yuan, 4.356 billion yuan, and 4.234 billion yuan respectively [1][2] - Jiangsu province leads in the number of IPOs with 10 companies, followed by Zhejiang and Guangdong provinces with 9 and 8 companies respectively [1] Group 2 - The ChiNext board has the highest fundraising amount at 10.124 billion yuan, followed by the Shanghai main board and the Sci-Tech Innovation Board at 9.489 billion yuan and 3.681 billion yuan respectively [2] - Seven companies raised over 1 billion yuan in their IPOs, with the top three being Tianyouwei, Kaifa Technology, and Xingfu Electronics, raising 3.740 billion yuan, 1.169 billion yuan, and 1.168 billion yuan respectively [2] - The growth in IPO financing is attributed to an increase in the number of IPO companies, while the individual financing scale remains stable compared to the previous year [2] Group 3 - Deloitte anticipates that the A-share market will continue to implement regulatory measures introduced in 2024, focusing on creating a high-quality and stable capital market [3] - The market is expected to prioritize quality and support technological innovation in new stock issuances, with an emphasis on mergers and acquisitions aimed at industrial integration and upgrading [3] - It is projected that the number of issuances and fundraising amounts will steadily increase compared to 2024 [3]

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

Group 1 - The company announced adjustments to the proposed investment amount and internal investment structure of the raised funds to ensure the smooth implementation of fundraising projects and improve the efficiency of fund usage [1][2][5] - The total amount raised from the initial public offering was RMB 1,090.1943 million, with a net amount of RMB 977.8911 million after deducting various issuance costs [1][2][25] - The company established a special account for the management and use of raised funds, which have been fully deposited in the account approved by the board of directors [1][25] Group 2 - The company adjusted the internal investment structure of the "Dialyzer (Ganzhou) Production Project" to prioritize construction costs over equipment purchases, ensuring efficient use of funds [3][5] - The adjustments will not change the total investment amount for the project, and the company plans to use self-raised funds for future equipment purchases as needed [3][5] Group 3 - The adjustments made by the company are based on actual fundraising conditions and business strategy, ensuring compliance with regulations and protecting shareholder interests [5][7][9] - The board of directors and the supervisory board approved the adjustments during meetings held on May 27, 2025, without the need for shareholder approval [6][17][41] Group 4 - The company plans to use up to RMB 170 million of the raised funds to increase capital in its wholly-owned subsidiary, Ganzhou Blood Purification Products Co., Ltd., to support the implementation of the fundraising project [12][13][14] - The increase in capital will be based on the funding needs of the subsidiary and will be executed within the approved limit [13][14] Group 5 - The company intends to use temporarily idle raised funds for cash management, with a maximum amount of RMB 740 million, to enhance fund efficiency and increase returns for shareholders [22][23][24] - The cash management will involve purchasing low-risk, liquid principal-protected products, ensuring that it does not affect the construction of fundraising projects [23][27][34] Group 6 - The company will replace self-raised funds previously invested in fundraising projects and paid issuance costs with raised funds, totaling RMB 27.67426 million [62][64][67] - This replacement will not affect the normal implementation of fundraising projects and complies with relevant regulations [67][69]

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司 二、募集资金投资项目基本情况及调整情况 根据《山东威高血液净化制品股份有限公司首次公开发行股票并在主板上市 招股说明书》和公司第二届董事会第十一次会议审议通过的《关于调整募集资金 投资项目拟投入募集资金金额、内部投资结构的议案》，公司募集资金投资项目 及投资计划如下： 单位：万元 | 序 | 募投项目名称 | 投资总额 | 调整前拟投入 | 调整后拟投入 | | --- | --- | --- | --- | --- | | 号 | | | 募集资金 | 募集资金 | | 1 | 威高血液净化智能化生产建设 项目 | 34,255.97 | 34,200.00 | 24,754.90 | | 2 | 透析器（赣州）生产建设项目 | 22,665.92 | 22,600.00 | 17,000.00 | | 3 | 威高新型血液净化高性能耗材 产品及设备研发中心建设项目 | 28,536.36 | 28,500.00 | 20,629.09 | | 4 | 威高血液净化数字化信息技术 平台建设项目 | 9,865.59 | 9,800.00 | 7 ...